Shots:
- The US FDA has granted 510(k) clearance to the OptaBlate BVN system for minimally invasive procedure designed to deliver long-lasting relief from vertebrogenic pain
- OptaBlate BVN achieves ≥1cm lesions in 7min. & features a steerable curved introducer, with microinfusion tech to minimize impedance & charring, plus 10-gauge access tools for precision
- OptaBlate BVN combines radiofrequency ablation & vertebral access to target the basivertebral nerve, providing relief from chronic vertebrogenic low back pain; Stryker to launch OptaBlate BVN at the ASPN 2025
Ref: Stryker| Image: Stryker | Press Release
Related News:- Genesys Spine Unveils Stasys-C 3DP Cervical Standalone System to Streamline Anterior Cervical Procedures
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
